Delivery Order SPE2DB22D2007-SPE2DB25FJ3UA
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of CAPLYTA 21 mg capsules (30-count units) with a ceiling value of $1,943.32. This non-set-aside, firm fixed-price delivery order is scheduled for completion by June 6, 2025, with performance taking place at the vendor's corporate office in Conshohocken, Pennsylvania. CAPLYTA (lumateperone) is an atypical antipsychotic medication used in the treatment of schizophrenia and...
- The Defense Logistics Agency awarded a delivery order valued at $2,384.16 to AmerisourceBergen Drug Corp for CAPLYTA (lumateperone) 21 mg capsules (quantity: 30) on August 14, 2025, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. CAPLYTA is an atypical antipsychotic medication used in the treatment of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 21 mg capsules (30-count units) under a firm fixed-price contract valued at $16,991.12. This non-competitive delivery order was issued on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. CAPLYTA is an atypical antipsychotic medication used in the treatment...
- The Defense Logistics Agency awarded a $14,646.30 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units). This is a firm fixed-price, non-set-aside contract with a completion deadline of June 3, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. CAPLYTA is a prescription antipsychotic medication used in the treatment of schizophrenia and bipolar depression, representing the type of...
- The Defense Logistics Agency awarded a $3,203.19 delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 MG capsules (30-count units) on August 28, 2025, with completion by August 29, 2025. This non-set-aside, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded a $22,965.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of CAPLYTA 10.5 mg capsules (quantity: 30 units). This is a competitively awarded contract with no set-aside designation, with performance to be completed by September 4, 2025, and fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of CAPLYTA 21 mg capsules (30-count) valued at $2,138.70 under a firm fixed-price contract. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The award was made without a...
- The Defense Logistics Agency awarded a delivery order valued at $3,210.29 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on July 18, 2025, with completion anticipated by July 21, 2025. This firm fixed price delivery order carries no set-aside designation and represents a competitive award to the prime contractor based in Conshohocken, Pennsylvania. CAPLYTA is an atypical antipsychotic medication used in the treatment of schizophrenia and bipolar disorder, reflecting...
- The Defense Logistics Agency (DLA) awarded a $11.82K delivery order to AmerisourceBergen Drug Corp on April 29, 2025, for the supply of CAPLYTA 42 mg capsules (30-count packaging), with performance completion scheduled for April 30, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order issued under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) valued at $1,067.73 under a firm fixed price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a non-competitive delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location, serving the federal medical supply chain...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3UADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of CAPLYTA 21 mg capsules (30-count units). This firm fixed-price delivery order, valued at $4,321.91, represents a non-set-aside award issued through competitive procurement. The contract is set for ultimate completion on August 8, 2025, with performance taking place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. CAPLYTA (lumateperone) is an atypical antipsychotic medication used in the treatment of schizophrenia and bipolar depression, reflecting the pharmaceutical supply requirements of federal military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to serve as a comprehensive global pharmaceutical supplier supporting military healthcare programs worldwide, delivering specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains. AmerisourceBergen's selection for this delivery order demonstrates its capability to meet federal procurement standards through open competition and its established role as a critical vendor within the Defense Health Agency and broader military medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 8/7/25 |